ODYSSEY HEALTH, INC.

LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is providing an update on its Asset Purchase Agreement with Oragenics, Inc. (NYSE: OGEN).

LAS VEGAS, NV / ACCESSWIRE / October 4, 2023 / Odyssey Health, Inc. (formerly known as Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), is a medical device and pharmaceutical company with a focus on life-enhancing medical solutions, today announced that its stock has commenced trading on the OTCQB Market ("OTCQB") after successfully up-listing from the OTC Pink Market.

Gains Nasal Delivery Technologies and Expands Product Pipeline Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY ) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as Odyssey’s proprietary powder formulation and its nasal delivery device. Odyssey will retain its other assets and operations.

LAS VEGAS, NV / ACCESSWIRE / August 23, 2023 / Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, recently presented at the Military Health System Research Symposium (MHSRS). Odyssey is developing a novel pharmaceutical, ONP-002, to be given intranasally for brain-targeted delivery in the acute through subacute period following mild traumatic brain injury (mTBI) also known as a concussion. MHSRS requested presentation submissions and after review, selected the Odyssey ONP-002 technology to be presented in poster-style at its yearly conference

LAS VEGAS, NV / ACCESSWIRE / June 8, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, recently presented at the Special Operations Medical Association (SOMA) - Scientific Assembly. Odyssey is developing a novel pharmaceutical, ONP-002 to be given intranasally for brain-targeted delivery in the acute through subacute period following mild traumatic brain injury (mTBI) aka concussion. SOMA requested presentation submissions and after review, they selected the Odyssey ONP-002 technology to be presented in poster-style at its yearly conference.

Las Vegas, NV, Sept. 28, 2022 — McapMediaWire — Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces the completion of all cohorts for its Phase I Single Ascending Dosing (SAD) and Multiple Ascending Dosing (MAD) clinical trial. Odyssey’s trial involved administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Throughout the trial, the drug was safe and well tolerated.

Millions of Americans suffer concussions every single year, which can be life-altering. But up to now, there is no cure for the often serious brain injury. For the first time in history, medical science is on track to not only diagnose but also treat concussions, with the combination of an FDA-approved test, new research that reveals its effectiveness, and a new treatment that is currently in human trials.

Las Vegas, NV, Aug. 10, 2022 (GLOBE NEWSWIRE) – Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial.

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial.

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and well-tolerated.